Eli Lilly and Company (NYSE: LLY) will present clinical data for its hematology treatments at the European Hematology Association Annual Meeting taking place June 11-14 in Stockholm, Sweden.

The company will share results from its Phase 3 BRUIN CLL-322 study in a late-breaking oral presentation. The study evaluated pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Lilly previously announced the study met its primary endpoint, showing statistically significant improvement in progression-free survival.

Ajax Therapeutics, which Lilly has agreed to acquire, will present first clinical data for AJ1-11095, a type II JAK2 inhibitor for patients with myelofibrosis who have failed treatment with a type I JAK2 inhibitor. The data comes from the Phase 1 AJX-101 study.

Kelonia Therapeutics, another company Lilly has agreed to acquire, will present additional data from its Phase 1 inMMyCAR study of KLN-1010, an anti-BCMA targeted in vivo CAR-T therapy for patients with relapsed and refractory multiple myeloma.

"The Phase 3 BRUIN CLL-322 results address an important question for patients with relapsed or refractory CLL," said Jacob Van Naarden, executive vice president and president of Lilly Oncology, according to the company's statement.

Both proposed acquisitions are subject to regulatory approvals and customary closing conditions. The Ajax Therapeutics transaction is expected to close in June 2026, while the Kelonia Therapeutics deal is expected to close in the second half of 2026.

Pirtobrutinib, marketed as Jaypirca, is currently approved by the FDA for treating adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously been treated with a covalent BTK inhibitor, and for relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy.